CHRS vs GILD: Which Stock is Better?
Side-by-side comparison of Coherus Oncology Inc and Gilead Sciences Inc in 2026
CHRS
Coherus Oncology Inc
$1.99
GILD
Gilead Sciences Inc
$135.87
Key Metrics Comparison
| Metric | CHRS | GILD | Winner |
|---|---|---|---|
| Market Cap | $296.78M | $170.84B | GILD |
| P/E Ratio | N/A | 20.27 | GILD |
| EPS (TTM) | $N/A | $6.79 | GILD |
| Revenue Growth | 0.6% | 0.0% | CHRS |
| Gross Margin | 67.2% | 78.8% | GILD |
Analyze CHRS
Full quant analysis
Analyze GILD
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is CHRS or GILD a better investment?
Comparing CHRS and GILD: Coherus Oncology Inc has a market cap of $296.78M while Gilead Sciences Inc has $170.84B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between CHRS and GILD?
CHRS (Coherus Oncology Inc) and GILD (Gilead Sciences Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: CHRS or GILD?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: CHRS or GILD?
CHRS has higher revenue growth at 0.6% vs 0.0% for GILD.
Which company is more profitable: CHRS or GILD?
Gilead Sciences Inc (GILD) has higher gross margins at 78.8% compared to 67.2% for CHRS.
Which is the larger company: CHRS or GILD?
Gilead Sciences Inc (GILD) is larger with a market cap of $170.84B compared to $296.78M for CHRS.
Should I buy CHRS or GILD in 2026?
Both CHRS and GILD have investment merit. CHRS trades at $1.99 while GILD trades at $135.87. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between CHRS and GILD stock?
Key differences: Market Cap ($296.78M vs $170.84B), P/E Ratio (N/A vs 20.3x), Revenue Growth (0.6% vs 0.0%), Gross Margin (67.2% vs 78.8%).